Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.43 |
| ▸ | PRCP | P42785 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123818 | 1.00 | IDH1 (0.43) | IDH1PRCPHTTNAAAEPHX2 | |
| SCHEMBL29795145 | 0.89 | NR1H3 (0.39) | IDH1 | |
| SCHEMBL24700281 | 0.82 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL23123300 | 0.82 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL23123708 | 0.82 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL29795151 | 0.75 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL23124076 | 0.73 | ALDH1A1 (0.35) | — | |
| SCHEMBL23123289 | 0.73 | ALDH1A1 (0.35) | — | |
| SCHEMBL23123839 | 0.70 | CHRM1 (0.41) | PRCPNAAAEPHX2EPHX1 | |
| SCHEMBL23123275 | 0.69 | PRCP (0.40) | PRCPHTTNAAAEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | IDH1 280/4885PRCP 626/4885HTT 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.